ONC's 2026 SVAP Standards Push EHR Vendors Toward FHIR US Core 9.0 and Da Vinci 2.2

Standards Update Changes Procurement Risk Calculus

The Office of the National Coordinator for Health Information Technology released its 2026 Approved SVAP standards for voluntary use in certified health IT modules, effective August 29, 2026. The approved set includes USCDI Version 6, HL7 FHIR US Core Implementation Guide STU 9.0.0, C-CDA Release 5.0.0, and the Da Vinci CRD 2.2.1, DTR 2.2.0, and PAS 2.2.1 implementation guides.

For enterprise buyers, this shifts procurement risk toward products already aligned with the newest interoperability stack. Even when voluntary, standards updates become de facto RFP requirements for organizations refreshing EHR, interoperability, and prior-authorization systems. The newer FHIR-based workflows reduce the need for custom interfaces between payer and provider systems, which directly affects integration budgets and timeline risk.

Vendors that already support the newer HL7 and Da Vinci stack gain an advantage over incumbents still tied to older FHIR or C-CDA profiles. This particularly affects EHRs, integration engines, prior-authorization tools, and payer-provider interoperability platforms. Buyers evaluating platforms in the next 12 months should ask vendors for their timeline to support FHIR US Core 9.0 and the updated Da Vinci guides, not whether they plan to support them.

M&A Wave Increases Vendor Roadmap Risk

Healthcare IT M&A remains active, with Capstone Partners reporting 179 announced or completed deals year-to-date in 2026, up 22.6% year over year. The firm characterizes the market as "robust" through 2026, signaling continued consolidation across software, services, and revenue-cycle segments.

Ongoing consolidation raises the odds of platform rationalization, packaging changes, and roadmap shifts after acquisition. These events directly affect renewal negotiations and vendor risk reviews. Buyers should expect larger suites and private-equity-backed rollups to pressure point applications, while standalone vendors will need stronger integration stories or niche differentiation to hold share.

Three recent deals illustrate where consolidation is concentrating:

Prior-authorization automation: R1 acquired Humata Health, an AI-powered prior-authorization company targeting touchless workflows. Prior-auth automation remains one of the clearest ROI areas in healthcare IT modernization because it reduces denials, manual labor, and cycle-time delays. The deal reshapes the vendor shortlist for revenue-cycle management and utilization-management projects, putting pressure on other prior-auth automation vendors and broader RCM suites marketing AI-assisted utilization management.

Predictive analytics and risk stratification: WellStack acquired DeLorean AI, a healthcare-focused AI company specializing in predictive analytics, risk stratification, and decision support. This moves WellStack further into the analytics layer, competing more directly with healthcare data platforms and AI decision-support vendors pitching risk scoring and operational intelligence. Predictive analytics and risk stratification remain budgeted areas for health systems and payer operations, especially when tied to utilization, care management, and financial performance.

Virtual specialty care: Switchboard Health acquired Livara Health and closed a $5 million funding round. Livara is a leader in virtual orthopedics and musculoskeletal management. MSK virtual care remains a common enterprise pilot area because it can reduce orthopedic episode cost and steer specialty utilization, especially for self-insured employers and payer networks. The deal strengthens competition against virtual specialty and musculoskeletal management vendors, while the new funding gives Switchboard more room to package specialty-care navigation and virtual MSK into employer and payer contracts.

Embedded Finance Emerges as Product Differentiator

Black Book Research argues that "the next healthcare IT revenue stream is credit," framing embedded financing into provider, patient, and reimbursement workflows as a key source of differentiation and transaction revenue. The report positions access to capital as a product feature, not a back-office function.

This points to growing interest in financing-enabled workflows in revenue cycle, patient pay, and provider purchasing, which may influence platform selection for vendors that can monetize payments and lending alongside core software. It favors vendors that can combine workflow software with embedded finance capabilities, putting pressure on pure-play RCM and billing platforms that lack capital-enabled product lines.

What to Watch

Buyers refreshing EHR, interoperability, or prior-authorization systems in the next 18 months should prioritize vendors with documented support for FHIR US Core 9.0 and the updated Da Vinci guides. Ask for a timeline, not a commitment. The difference between a vendor shipping support in Q4 2026 versus Q2 2027 can determine whether you need to carry custom interfaces through another budget cycle.

For vendors under private-equity ownership or rumored to be exploring a sale, request contractual language addressing roadmap continuity and migration support in the event of acquisition. The 22.6% year-over-year increase in healthcare IT M&A means the odds of a vendor being acquired or merged during a three-year contract are material, not hypothetical.